A phase 1 trial of alisertib and romidepsin for relapsed/refractory aggressive B-cell and T-cell lymphomas

Ngā tūemi rite

• A phase 1 trial of alisertib and romidepsin for relapsed/refractory aggressive B-cell and T-cell lymphomas
  mā: Paolo Strati, me ētahi atu.
  I whakaputaina: (2020-01-01)
• Efficacy of ifosfamide, carboplatin and etoposide chemotherapy protocol in relapsed refractory germ cell tumors
  mā: Musa Barış Aykan, me ētahi atu.
  I whakaputaina: (2022-09-01)
• Bortezomib, Ifosfamide, Carboplatin, and Etoposide in a Patient with HIV-Negative Relapsed Plasmablastic Lymphoma
  mā: Mehmet Akce, me ētahi atu.
  I whakaputaina: (2016-01-01)
• Outcome and toxicity of ifosfamide, carboplatin, and etoposide versus gemcitabine and vinorelbine regimen for pediatric patients with relapsed or refractory Hodgkin’s lymphoma
  mā: Ahmed Mahdy, me ētahi atu.
  I whakaputaina: (2023-06-01)
• Nivolumab plus ifosfamide, carboplatin, and etoposide are a highly effective first salvage regimen in high‐risk relapsed/refractory Hodgkin lymphoma
  mā: Matthew Mei, me ētahi atu.
  I whakaputaina: (2025-05-01)